{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:57:47Z","timestamp":1793761067107,"version":"4.6.1"},"reference-count":99,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018921","name":"Yulin Science and Technology Bureau","doi-asserted-by":"publisher","award":["2024-SF-024"],"award-info":[{"award-number":["2024-SF-024"]}],"id":[{"id":"10.13039\/100018921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303811"],"award-info":[{"award-number":["82303811"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017596","name":"Natural Science Basic Research Program of Shaanxi Province","doi-asserted-by":"publisher","award":["2023-JC-QN-0840"],"award-info":[{"award-number":["2023-JC-QN-0840"]}],"id":[{"id":"10.13039\/501100017596","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014544","name":"Institute for Health Metrics and Evaluation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007812","name":"University of Washington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["LISBOA2030-FEDER-00862500-14998"],"award-info":[{"award-number":["LISBOA2030-FEDER-00862500-14998"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Biotechnology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tibtech.2025.12.020","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T13:33:54Z","timestamp":1771248834000},"page":"2511-2529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advancements and challenges in CAR-NK cell therapy for cancer treatment"],"prefix":"10.1016","volume":"44","author":[{"given":"Zhengshui","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yundong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changchun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengliang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danwen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narmatha","family":"Chellamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manimurugan","family":"Shanmuganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8422-6792","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Conde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tibtech.2025.12.020_bb0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","article-title":"Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy","volume":"14","author":"Gong","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0010","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0020","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0025","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0035","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.3390\/cells10123356","article-title":"Chimeric antigen receptors expand the repertoire of antigenic macromolecules for cellular immunity","volume":"10","author":"Keane","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0040","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4103\/ijp.ijp_531_20","article-title":"Chimeric antigen receptor T cell: a cancer immunotherapy","volume":"54","author":"Singh","year":"2022","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0045","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0050","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.3390\/cells10123390","article-title":"NK cells armed with chimeric antigen receptors (CAR): roadblocks to successful development","volume":"10","author":"Bashiri Dezfouli","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0055","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36688","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Morrissey","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0060","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: from basic biology to clinical development","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0065","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1172\/JCI129338","article-title":"Killers 2.0: NK cell therapies at the forefront of cancer control","volume":"129","author":"Hodgins","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0070","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.3390\/ijms20184514","article-title":"NK cell hyporesponsiveness: more is not always better","volume":"20","author":"Frutoso","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0075","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.3389\/fimmu.2019.02590","article-title":"JAK\/STAT cytokine signaling at the crossroad of NK cell development and maturation","volume":"10","author":"Gotthardt","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0080","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0085","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.925985","article-title":"CAR T-cell-based gene therapy for cancers: new perspectives, challenges and clinical developments","volume":"13","author":"Jogalekar","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0095","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/14787210.2021.1855143","article-title":"CAR-T cell therapy and infection: a review","volume":"19","author":"Bupha-Intr","year":"2021","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0100","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0105","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/08830185.2022.2102619","article-title":"B7-H3-targeted CAR-T cell therapy for solid tumors","volume":"41","author":"Li","year":"2022","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100804","article-title":"Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells","volume":"6","author":"Li","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0115","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12943-023-01894-9","article-title":"Outsmarting trogocytosis to boost CAR NK\/T cell therapy","volume":"22","author":"Ramezani","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-023-01435-3","article-title":"CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022","volume":"16","author":"Huang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0125","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0130","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0135","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0140","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0145","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0150","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma","volume":"9","author":"Ernst","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0155","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic natural killer cell therapy","volume":"141","author":"Berrien-Elliott","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0160","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2020.100870","article-title":"NK cells and ILCs in tumor immunotherapy","volume":"80","author":"Sivori","year":"2021","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0170","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-022-01382-5","article-title":"Natural killer cells in clinical development as non-engineered, engineered and combination therapies","volume":"15","author":"Lamers-Kok","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101073","article-title":"Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting","volume":"60","author":"Merino","year":"2023","journal-title":"Blood Rev."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0180","first-page":"5559","article-title":"CAR-NK cells for acute myeloid leukemia immunotherapy: past, present and future","volume":"13","author":"Zhang","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.673276","article-title":"CAR-NK cell: a new paradigm in tumor immunotherapy","volume":"11","author":"Marofi","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108587","article-title":"Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages","volume":"106","author":"Ebrahimiyan","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1070961","article-title":"PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0205","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0210","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0215","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/ijd.14945","article-title":"Adoptive cell transfer (ACT) of autologous tumor-infiltrating lymphocytes (TILs) to treat malignant melanoma: the dawn of a chimeric antigen receptor T (CAR-T) cell therapy from autologous donor","volume":"59","author":"Roncati","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0220","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ymthe.2019.02.017","article-title":"Adoptive cell therapy: ACT-up or ACT-out?","volume":"27","author":"Brenner","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0225","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","article-title":"New development in CAR-T cell therapy","volume":"10","author":"Wang","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0230","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0235","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia","volume":"105","author":"Inaba","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0240","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc3930","article-title":"Building better monoclonal antibody-based therapeutics","volume":"15","author":"Weiner","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103915","article-title":"Monoclonal antibodies in breast cancer: a critical appraisal","volume":"183","author":"Behl","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0250","doi-asserted-by":"crossref","first-page":"7157","DOI":"10.18632\/oncotarget.12702","article-title":"Targeting immune checkpoints in malignant glioma","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0255","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","article-title":"Natural killer cells in cancer biology and therapy","volume":"19","author":"Wu","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0260","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.3389\/fimmu.2019.02836","article-title":"Harnessing NK cells for cancer treatment","volume":"10","author":"Minetto","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0265","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","article-title":"Human natural killer cells","volume":"112","author":"Caligiuri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0270","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.cell.2020.02.029","article-title":"Snapshot: natural killer cells","volume":"180","author":"Crinier","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0275","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","article-title":"Natural killer cell therapies","volume":"626","author":"Vivier","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0280","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41577-019-0139-2","article-title":"Immunometabolism and natural killer cell responses","volume":"19","author":"O\u2019Brien","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0285","doi-asserted-by":"crossref","first-page":"19932","DOI":"10.18632\/oncotarget.4841","article-title":"NK cells in asthma exacerbation","volume":"6","author":"Lunding","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0290","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1600-065X.1997.tb00944.x","article-title":"Human NK cells: their ligands, receptors and functions","volume":"155","author":"Reyburn","year":"1997","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0295","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1016\/j.molimm.2008.06.016","article-title":"NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways","volume":"45","author":"Verhoeven","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0300","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250198","article-title":"NKG2D engagement on human NK cells leads to DNAM-1 hypo-responsiveness through different converging mechanisms","volume":"53","author":"Milito","year":"2023","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0305","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/178698","article-title":"NKG2D and DNAM-1 ligands: molecular targets for NK cell-mediated immunotherapeutic intervention in multiple myeloma","volume":"2015","author":"Fionda","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0310","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0315","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0320","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13791","article-title":"Revolutionising cancer immunotherapy: advancements and prospects in non-viral CAR-NK cell engineering","volume":"58","author":"Zhou","year":"2025","journal-title":"Cell Prolif."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0325","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000873","article-title":"Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines","volume":"8","author":"Park","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0330","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13045-021-01216-w","article-title":"Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity","volume":"14","author":"Wang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0335","doi-asserted-by":"crossref","first-page":"8439","DOI":"10.1038\/s41467-024-52388-1","article-title":"CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells","volume":"15","author":"Bexte","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1231916","article-title":"KLRC1 knockout overcomes HLA-E-mediated inhibition and improves NK cell antitumor activity against solid tumors","volume":"14","author":"Mac Donald","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0345","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/icb.2017.6","article-title":"Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells","volume":"95","author":"Ochoa","year":"2017","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0350","doi-asserted-by":"crossref","first-page":"E10915","DOI":"10.1073\/pnas.1811615115","article-title":"IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages","volume":"115","author":"Zhang","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0355","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.immuni.2023.11.018","article-title":"Circulating NK cells establish tissue residency upon acute infection of skin and mediate accelerated effector responses to secondary infection","volume":"57","author":"Torcellan","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0360","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1002\/eji.201344072","article-title":"NK cells gain higher IFN-\u03b3 competence during terminal differentiation","volume":"44","author":"Luetke-Eversloh","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0365","doi-asserted-by":"crossref","DOI":"10.1038\/srep18159","article-title":"IFN-\u03b3 modulates Ly-49 receptors on NK cells in IFN-\u03b3-induced pregnancy failure","volume":"5","author":"Li","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0370","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/eji.201444903","article-title":"IFN-\u03bb-mediated IL-12 production in macrophages induces IFN-\u03b3 production in human NK cells","volume":"45","author":"de Groen","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.jri.2021.103367","article-title":"NK cells that differ in expression of NKp46 might play different roles in endometrium","volume":"147","author":"Mai","year":"2021","journal-title":"J. Reprod. Immunol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0380","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1073\/pnas.1222047110","article-title":"Contribution of Thy1+ NK cells to protective IFN-\u03b3 production during Salmonella typhimurium infections","volume":"110","author":"Kupz","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0385","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/icb.2013.99","article-title":"TLR-mediated activation of NK cells and their role in bacterial\/viral immune responses in mammals","volume":"92","author":"Adib-Conquy","year":"2014","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0390","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911117","article-title":"CD3(+)\/CD56(+) NKT-like cells show imbalanced control immediately after exercise in delayed-onset muscle soreness","volume":"23","author":"Sonkodi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0395","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.992723","article-title":"CD56-negative NK cells: frequency in peripheral blood, expansion during HIV-1 infection, functional capacity and KIR expression","volume":"13","author":"Cocker","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0400","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1046\/j.1365-2249.2002.01721.x","article-title":"CD3+ CD56+ NK T cells are significantly decreased in the peripheral blood of patients with psoriasis","volume":"127","author":"Koreck","year":"2002","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0405","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/cmi.2014.26","article-title":"CD56brightCD25+ NK cells are preferentially recruited to the maternal\/fetal interface in early human pregnancy","volume":"12","author":"Tao","year":"2015","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0410","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3390\/v13020156","article-title":"Influenza A virus hemagglutinin and other pathogen glycoprotein interactions with NK cell natural cytotoxicity receptors NKp46, NKp44 and NKp30","volume":"13","author":"Luczo","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0415","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/cei.13422","article-title":"Low-dose IL-2 induces CD56bright NK regulation of T cells via NKp44 and NKp46","volume":"200","author":"McQuaid","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0420","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-bioeng-070620-033348","article-title":"In situ programming of CAR T cells","volume":"23","author":"Parayath","year":"2021","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0425","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713364","article-title":"CAR-NK cells generated with mRNA-LNPs kill tumor target cells in vitro and in vivo","volume":"24","author":"Golubovskaya","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0430","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1016\/j.ymthe.2025.06.036","article-title":"Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation","volume":"33","author":"Andorko","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0435","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1574742","article-title":"CAR-NK cell therapy: promise and challenges in solid tumors","volume":"16","author":"Balkhi","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0440","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3390\/biom15070935","article-title":"Overcoming immune barriers in allogeneic CAR-NK therapy: from multiplex gene editing to AI-driven precision design","volume":"15","author":"Kim","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0445","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.ymthe.2024.11.035","article-title":"Managing allorejection in off-the-shelf CAR-engineered cell therapies","volume":"33","author":"Li","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0450","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.586168","article-title":"HLA class I knockout converts allogeneic primary NK cells into suitable effectors for \u2018off-the-shelf\u2019 immunotherapy","volume":"11","author":"Hoerster","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0455","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-025-01737-8","article-title":"Recent advances in universal chimeric antigen receptor T cell therapy","volume":"18","author":"Jiang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0460","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0465","doi-asserted-by":"crossref","first-page":"8809","DOI":"10.1038\/s41467-025-63863-8","article-title":"Selective HLA knockdown and PD-L1 expression prevent allogeneic CAR-NK cell rejection and enhance safety and anti-tumor responses in xenograft mice","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0470","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200839","article-title":"The SIRP\u03b1-CD47 immune checkpoint in NK cells","volume":"218","author":"Deuse","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0475","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-024-07443-8","article-title":"Engineered CD47 protects T cells for enhanced antitumour immunity","volume":"630","author":"Yamada-Hunter","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0480","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.tibtech.2025.12.020_bb0485","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jcyt.2025.06.006","article-title":"CAR-NK cells to treat patients with cancer: a systematic scoping review of published studies and registered clinical trials","volume":"27","author":"Rana","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0490","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/j.ccell.2025.09.013","article-title":"Engineered natural killer cells for cancer therapy","volume":"43","author":"Biederst\u00e4dt","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tibtech.2025.12.020_bb0495","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3390\/vaccines13060654","article-title":"CAR beyond \u03b1\u03b2 T cells: unleashing NK cells, macrophages, and \u03b3\u03b4 T lymphocytes against solid tumors","volume":"13","author":"Xian","year":"2025","journal-title":"Vaccines"}],"container-title":["Trends in Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779925005414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779925005414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:14:58Z","timestamp":1788362098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167779925005414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":99,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0167779925005414"],"URL":"https:\/\/doi.org\/10.1016\/j.tibtech.2025.12.020","relation":{},"ISSN":["0167-7799"],"issn-type":[{"value":"0167-7799","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancements and challenges in CAR-NK cell therapy for cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Trends in Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tibtech.2025.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}